SCHEMBL16508264

SCHEMBL16508264

CCc1cc(-c2ccc[nH]c2=O)c2cnc(-c3ccc(NS(C)(=O)=O)cc3)cc2c1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.49
IDO1 P14902 3/20 0.44
TDO2 P48775 3/20 0.44
PIP4K2A P48426 1/20 0.39
PIP4K2B P78356 1/20 0.39
PIP4K2C Q8TBX8 1/20 0.39
IKBKB O14920 2/20 0.37
CHUK O15111 2/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
TYK2 P29597 1/20 0.37
JAK3 P52333 1/20 0.37
BACE1 P56817 1/20 0.35
MAPK10 P53779 2/20 0.35
CYP17A1 P05093 1/20 0.35
CLK1 P49759 1/20 0.35
DYRK1A Q13627 1/20 0.35
DYRK2 Q92630 1/20 0.35
DYRK1B Q9Y463 1/20 0.35
PIK3CD O00329 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1703305 0.87 CYP3A4 (0.57) CYP3A4IDO1TDO2PIP4K2APIP4K2B
SCHEMBL16508299 0.86 CYP3A4 (0.49) CYP3A4IDO1TDO2PIP4K2APIP4K2B
SCHEMBL16508295 0.84 CYP3A4 (0.49) CYP3A4PIP4K2APIP4K2BPIP4K2CMAPK10
SCHEMBL15188916 0.84 CYP3A4 (0.49) CYP3A4IDO1TDO2PIP4K2APIP4K2B
SCHEMBL1703309 0.73 CYP3A4 (0.57) CYP3A4IDO1TDO2PIP4K2APIP4K2B
SCHEMBL625962 0.73 CYP3A4 (0.57) CYP3A4IDO1TDO2PIP4K2APIP4K2B
SCHEMBL16508267 0.71 NPC1 (0.41) CYP3A4PIP4K2APIP4K2BPIP4K2CIKBKB
SCHEMBL1702764 0.71 CYP3A4 (0.57) CYP3A4PIP4K2APIP4K2BPIP4K2CMAPK10
SCHEMBL16508262 0.70 DYRK1B (0.41) IKBKBCHUKMAPK10CYP17A1CLK1
SCHEMBL2450318 0.69 CYP3A4 (0.51) CYP3A4PIP4K2APIP4K2BPIP4K2CMAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110300103-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC (US) 2011-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110300103-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, ZC3HAV1, IRF3 CYP3A4 55/4885IDO1 1306/4885TDO2 3976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.